Immix Biopharma (IMMX) Competitors

Immix Biopharma (NASDAQ:IMMX) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership.

Does the media refer more to IMMX or TERN?

In the previous week, Immix Biopharma had 9 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 12 mentions for Immix Biopharma and 3 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.52 beat Immix Biopharma's score of 0.74 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Terns Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts prefer IMMX or TERN?

Immix Biopharma presently has a consensus target price of $7.00, indicating a potential upside of 178.88%. Terns Pharmaceuticals has a consensus target price of $15.63, indicating a potential upside of 281.75%. Given Terns Pharmaceuticals' higher possible upside, analysts plainly believe Terns Pharmaceuticals is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Terns Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Is IMMX or TERN more profitable?

Terns Pharmaceuticals' return on equity of -32.76% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-102.68%	-80.89%
Terns Pharmaceuticals	N/A	-32.76%	-31.33%

Do insiders and institutionals have more ownership in IMMX or TERN?

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. 55.4% of Immix Biopharma shares are owned by insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community favor IMMX or TERN?

Terns Pharmaceuticals received 32 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 60.27% of users gave Terns Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Immix Biopharma	Outperform Votes 12 100.00%	Underperform Votes No Votes
Terns Pharmaceuticals	Outperform Votes 44 60.27%	Underperform Votes 29 39.73%

Which has stronger earnings and valuation, IMMX or TERN?

Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$15.43M	-$0.70	-3.59
Terns Pharmaceuticals	N/A	N/A	-$90.21M	-$1.09	-3.76

Which has more risk and volatility, IMMX or TERN?

Immix Biopharma has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500.

Summary

Immix Biopharma beats Terns Pharmaceuticals on 8 of the 15 factors compared between the two stocks.